Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NEOVIVA project receives Bpifrance funding
May 2019
SHARING OPTIONS:

STRASBOURG, France—Biotech company Transgene recently announced that its NEOVIVA project was chosen by Bpifrance’s “Investments for the Future” Programme for the development of an industrial sector focused on myvac, Transgene’s individualized immunotherapy platform. Per the agreement, the NEOVIVA project will receive €5.2 million over the course of five years, €2.6 million of which will go to Transgene. The NEOVIVA project is seeking to develop and validate a manufacturing approach that could provide all necessary solutions for developing individualized immunotherapies. Two proof-of-concept clinical trials are in the works in Europe and the United States, which are slated to start in the second half of 2019. Transgene is partnering on this project with HalioDx, Traaser and the Curie Institute.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.